Quantum-Si
Quantum-Si's revenue fell 20.3% to $2 million in fiscal 2025. Its operating margin was −4,766.0%, down from −3,550.6% a year earlier. Free cash flow was −$97 million. The diluted share count rose 38.1%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
Income statement
Quantum-Si lost money in fiscal 2025: a net loss of $101 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 471 | — | 134 | 210 | 216 |
| Debt incl. finance leases | 0 | 0 | 0 | 0 | 0 |
| Net debt (negative means net cash) | −471 | — | −134 | −210 | −216 |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | 0.0x | 0.0x | 0.0x | 0.0x | 0.0x |
| Interest coverage | −19,381.6x | — | — | — | — |
| Current ratio | 41.4x | 22.8x | 22.9x | 12.0x | 7.6x |
| Quick ratio | 41.4x | 22.8x | 22.6x | 11.8x | 7.5x |
Cash flow
Projections
Project Quantum-Si's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, 2 insiders bought $564,396 of Quantum-Si shares on the open market, and 4 insiders sold $494,746.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 22, 2026 | Jeffrey Alan HawkinsPresident & CEO, Director | Sold | 9,709 | $0.76 | $7,379 | Form 4 |
| Sep 22, 2026 | Christian LaPointeGC & Corp. Secretary | Sold | 4,721 | $0.76 | $3,588 | Form 4 |
| Sep 22, 2026 | Jeffry R. KeyesChief Financial Officer | Sold | 2,493 | $0.76 | $1,895 | Form 4 |
| Sep 21, 2026 | Jeffrey Alan HawkinsPresident & CEO, Director | Sold | 20,143 | $0.76 | $15,309 | Form 4 |
| Sep 21, 2026 | Christian LaPointeGC & Corp. Secretary | Sold | 9,795 | $0.76 | $7,444 | Form 4 |
| Sep 21, 2026 | Jeffry R. KeyesChief Financial Officer | Sold | 5,172 | $0.76 | $3,931 | Form 4 |
| Jun 23, 2026 | John S. VieceliChief Product Officer | Sold | 15,112 | $0.90 | $13,601 | Form 4 |
| Jun 23, 2026 | Jeffrey Alan HawkinsPresident & CEO, Director | Sold | 11,311 | $0.90 | $10,180 | Form 4 |
| Jun 23, 2026 | Christian LaPointeGC & Corp. Secretary | Sold | 7,794 | $0.90 | $7,015 | Form 4 |
| Jun 23, 2026 | Jeffry R. KeyesChief Financial Officer | Sold | 4,117 | $0.90 | $3,705 | Form 4 |
| Jun 22, 2026 | John S. VieceliChief Product Officer | Sold | 15,111 | $0.96 | $14,507 | Form 4 |
| Jun 22, 2026 | Jeffrey Alan HawkinsPresident & CEO, Director | Sold | 11,310 | $0.96 | $10,858 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 4 of 8 | 3 of 9 | 1 of 9 |
| Rule of 40 | — | −2,838.2% | −4,011.9% |
| Altman Z'' | 8.39 | 1.47 | 0.75 |
| Accruals ratio | −0.6% | −4.8% | −2.7% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Pass | Fail | Fail |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | Fail | Fail | Fail |
| Current ratio rose | Pass | Fail | Fail |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | — | Pass | Fail |
| Revenue rose relative to assets | Pass | Pass | Fail |
| F-score | 4 of 8 | 3 of 9 | 1 of 9 |
Compare
Put Quantum-Si side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Quantum-Si | FY25 | −20.3% | −4,766.0% | −3,991.5% | — | — | 1 | |
| OneMedNet | FY25 | 111.3% | −711.3% | −553.0% | — | — | — | Compare |
| bioAffinity Technologies | FY25 | −34.2% | −171.6% | −152.4% | −400.1% | — | 3 | Compare |
| Seer | FY25 | 17.0% | −470.4% | −278.9% | — | — | — | Compare |
| OmniAb | FY25 | −29.3% | −369.5% | −198.3% | — | — | — | Compare |
7 years of figures
| Fiscal year | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | — | — | 0 | 0 | 1 | 3 | 2 |
| Revenue growth | — | — | — | — | — | 182.6% | −20.3% |
| Gross profit | — | — | 0 | 0 | 0 | 2 | 1 |
| Research and development | 28 | 28 | 47 | 72 | 67 | 60 | 54 |
| Operating income | −37 | −37 | −97 | −124 | −111 | −109 | −116 |
| Net income | −36 | −37 | −95 | −132 | −96 | −101 | −101 |
| Diluted EPS (US$) | −6.95 | −6.84 | −1.19 | −0.95 | −0.68 | −0.71 | −0.51 |
| Diluted shares (millions) | 5 | 5 | 80 | 139 | 141 | 143 | 198 |
| Cash flow | |||||||
| Cash from operations | −31 | −33 | −67 | −91 | −94 | −88 | −95 |
| Capital expenditure | 1 | 0 | 6 | 11 | 4 | 5 | 2 |
| Free cash flow | −32 | −33 | −73 | −101 | −99 | −92 | −97 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 5 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 3 | 2 | 25 | 11 | 8 | 9 | 11 |
| Balance sheet at fiscal year end | |||||||
| Cash and short-term investments | 33 | 37 | 471 | — | 134 | 210 | 216 |
| Debt incl. finance leases | — | 2 | 0 | 0 | 0 | 0 | 0 |
| Total assets | — | 41 | 503 | 392 | 298 | 248 | 246 |
| Total liabilities | — | 4 | 26 | 33 | 27 | 32 | 25 |
| Shareholders' equity | −125 | −160 | 477 | 359 | 272 | 215 | 220 |
| Margins and ratios | |||||||
| Gross margin | — | — | — | — | 45.1% | 52.3% | 47.3% |
| Operating margin | — | — | — | — | −10,274.6% | −3,550.6% | −4,766.0% |
| Net margin | — | — | — | — | −8,868.8% | −3,303.0% | −4,160.1% |
| Free cash flow margin | — | — | — | — | −9,107.8% | −3,020.9% | −3,991.5% |
| Rule of 40 (growth + FCF margin) | — | — | — | — | — | −2,838.2% | −4,011.9% |
| Return on capital | — | — | — | — | — | −119.5% | — |
| Return on equity | — | — | −59.9% | −31.7% | −30.4% | −41.5% | −46.5% |
| Return on assets | — | — | −34.9% | −29.6% | −27.8% | −37.0% | −41.1% |
| Net debt to EBITDA | — | — | — | — | — | — | — |